Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases ...

Novel Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy (“SADA PRIT”) platform designed to improve upon traditional radioimmunotherapy by delivering high therapeutic dose while minimizing ...

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma ...

More than 8,000 healthcare professionals will descend on San Francisco starting Monday for the 43rd annual J.P. Morgan ...

Management will also participate and present at the Biotech Showcase conference alongside the J.P. Morgan Healthcare Conference in San Francisco. 43 rd Annual J.P. Morgan Healthcare Conference – ...

STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup.

The presentation will be webcast live and available for replay in the Investors section of OPKO Health’s website here.

J.P. Morgan releases its quarterly look-ahead days before the entire biopharma industry descends on San Francisco for the ...

Shareholders have asked for details about how UnitedHealth Group's tactics that curb care have affected patients. This comes as a Texas doctor details her frustrating experience with the insurer.

J.P. Morgan is hosting a three-panel women's health series at this year's conference to highlight the importance of innovation and growing visibility around women's health.

FY2024 revenue up 7% YoY, driven by international demand. Find out why I am upgrading CTKB stock from Hold to Buy.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...